Trial reportEuropean journal of medical research2025
Efficacy of semilunar ganglion radiofrequency thermal coagulation in moderate and severe trigeminal postherpetic neuralgia and its impact on serum IL-1β and IL-6 levels.
Trial report in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTrigeminal postherpetic neuralgia (TPHN) represents a severe neuropathic pain syndrome with challenging therapeutic management. While radiofrequency thermocoagulation (RF-TC), a minimally invasive neuromodulation technique, has demonstrated favorable outcomes in treating thoracoabdominal and lumbosacral PHN, its clinical application in trigeminal nerve distributions remains underexplored.
objectiveTo evaluate gasserian ganglion RF-TC efficacy in moderate-to-severe TPHN and its effects on serum IL-1β and IL-6 levels.
methodsThis study enrolled 120 eligible patients diagnosed with TPHN at the Department of Cerebrovascular Diseases, Hangzhou Third People's Hospital, between January 2024 and December 2024. Patients were stratified into moderate (n = 60) and severe (n = 60) pain cohorts based on baseline pain severity. Severe PHN patients were randomly assigned to either the RF-TC group (Group A, n = 30) or the control group (Group B, n = 30), while moderate PHN patients were randomized to the RF-TC group (Group C, n = 30) or the control group (Group D, n = 30). All RF-TC procedures were performed via a foramen ovale approach under digital subtraction angiography (DSA) guidance. Visual Analogue Scale (VAS) scores and serum cytokine levels (IL-1β, IL-6) were quantified pre-treatment and at 1-/4-week post-intervention using standardized ELISA protocols.
resultsRF-TC groups (A/C) demonstrated significantly lower VAS scores and reduced serum IL-1β/IL-6 concentrations compared to controls (B/D) at both follow-ups (all p < 0.01), with enhanced therapeutic magnitude observed in severe cases. These findings indicate RF-TC's dual mechanism of pain alleviation and systemic anti-inflammatory modulation.
conclusionGasserian ganglion RF-TC is a safe, effective TPHN treatment, achieving significant pain reduction and proinflammatory cytokine suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.